文献速递消化道肿瘤放疗

临床T1N0M0期食管鳞状细胞癌根治性放疗:多中心回顾性研究(KROG 21-10)

Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: A multicenter retrospective study (KROG 21-10).
PubMed 文献 · Radiother Oncol · 2023-09-30

该多中心回顾性分析纳入2010至2019年接受根治性放疗的168例临床T1N0M0期食管鳞状细胞癌患者,中位随访34.0个月,评估失败模式及治疗方案。cT1a与cT1b患者失败率相似,cT1b患者中选择性淋巴结照射与累及野照射在无局部区域复发生存及总生存上无差异。

要点

  • cT1a患者3年局部区域复发率30.5%,cT1b患者27.1%,失败率相似。
  • cT1b患者中ENI与IFI的3年FFLRR无差异(P=0.831)。
  • 同步化疗与FFLRR边缘相关(HR 0.16,P=0.064)。

核心结论

  • 不能接受内镜下切除的cT1a患者失败率与cT1b患者相似,对分期准确性提出疑问,并提示需要如放化疗的充分治疗。
  • cT1b患者中,累及野照射50至60 Gy联合同步化疗可能是合理的。

研究设计与样本

  • 多机构回顾性分析,纳入2010至2019年接受根治性放疗的T1N0M0期食管鳞状细胞癌患者。
  • 共纳入168例患者,中位随访34.0个月,其中cT1a 26例、cT1b 116例。
  • 在cT1b患者中进行倾向性评分匹配。

主要发现

  • cT1a患者3年全部复发率和局部区域复发率分别为30.5%和24.1%,cT1b患者分别为27.1%和25.9%。
  • 116例cT1b患者中,69例接受选择性淋巴结照射(ENI),47例接受累及野照射(IFI)。
  • 倾向性评分匹配后,3年无局部区域复发生存(FFLRR)率为84.5%。
  • ENI与IFI在FFLRR(P=0.831)和总生存(OS,P=0.525)上无差异。
  • IFI组3年FFLRR为83.8%(95%CI 61.8-93.8%),ENI组为85.3%(95%CI 65.1-94.3%)。

关键数值与推荐

  • 多因素分析中,同步化疗使用与FFLRR边缘相关(风险比0.16,P=0.064)。
  • cT1b患者中,IFI联合50至60 Gy放疗及同步化疗可能是合理的。

临床怎么用

  • 作者认为,不能接受内镜下切除的cT1a患者失败率与cT1b相似,提示需要如放化疗的充分治疗。
  • 作者认为,cT1b患者中IFI联合50至60 Gy及同步化疗可能是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the failure pattern and analyze the treatment scheme of definitive radiation therapy (RT) for T1N0M0 esophageal squamous cell carcinoma (ESCC). METHODS: We performed a multi-institutional retrospective analysis in T1N0M0 ESCC patients who underwent definitive RT from 2010 to 2019. Patterns of failure were demonstrated as in-, and out-field locoregional, and distant metastasis. In the analysis, freedom-from locoregional recurrence (FFLRR) and their association with clinicopathologic factors were evaluated. Propensity score matching in cT1b patients was done. RESULTS: 168 patients were included with a median follow-up of 34.0 months, and 26 cT1a, 116 cT1b disease. The rates of 3-year all and locoregional recurrence for cT1a were 30.5% and 24.1% and those for cT1b were 27.1% and 25.9%, respectively. Among 116 cT1b patients, 69 patients received elective nodal irradiation (ENI) and 47 received involved field irradiation (IFI). After propensity score matching, the 3-year FFLRR rate was 84.5%. There was no difference between ENI and IFI in FFLRR (P = 0.831) and OS (P = 0.525). The 3-year FFLRR was 83.8% (95% Confidence interval (CI), 61.8-93.8%) in IFI group and 85.3% (95% CI, 65.1-94.3%) in ENI group. In multivariate analysis, concurrent chemotherapy use was marginally associated with FFLRR (Hazard ratio, 0.16; P = 0.064). CONCLUSION: cT1a patients who cannot receive endoscopic resection showed similar failure rates as cT1b patients, questioning the staging accuracy and raised the need for thorough treatment like chemoradiotherapy. In cT1b patients, IFI with 50 to 60 Gy and concurrent chemotherapy could be reasonable.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Song JY, Moon SH, Suh YG, et al. Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: A multicenter retrospective study (KROG 21-10). Radiother Oncol. 2023. PMID: 37783290. doi:10.1016/j.radonc.2023.109936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。